Health Condition 1: N390- Urinary tract infection, site notspecified
Conditions
Interventions
Intervention1: Cystone GNX tablets: This is an open label, two arm, randomized, comparative clinical study. Initially, subjects will be initiated for the informed consent process and then screening wi
Sponsors
The Himalaya Drug Company
Eligibility
Inclusion criteria
Inclusion criteria: Adult male and female subjects aged >=18 to Three or more episodes of recurrent UTI in the past 12 months. UTI as diagnosed by urine culture more than 105 CFU/mL Subjects willing to sign informed consent and follow the study procedure. Subjects who has not participated in any similar kind of clinical study in the last one month.
Exclusion criteria
Exclusion criteria: History of neurogenic bladder, pelvic irradiation or chemical cystitis, presence of urethral, pelvic, or rectal carcinoma, benign or malignant bladder tumors, tuberculous cystitis. Kidney Infection Pre-existing urolithiasis condition Pre-existing systemic disease: cardiac, neurological, renal or hepatic dysfunction. Antibacterial drug therapy for UTI during the previous 72 hours Patients with suspected or confirmed prostatitis Patients with renal transplantation or ileal loops History of urinary tract structural abnormalities. Any recent history of trauma to the pelvis or urinary tract. Pregnant & breast-feeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjects demonstrating percentage improvement in the terms of efficacy parameters such as laboratory and clinical parameters from baseline to end of study.Timepoint: The subject will be assessed clinically at day 1, day 14 plus or minus 2 days and at day 28 plus or minus 2 days (End of Study). | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety evaluation through Incidence of adverse events during the study period. Compliance of the subject to the study medication Timepoint: The subject will be assessed clinically at day 1, day 14 plus or minus 2 days and at day 28 plus or minus 2 days (End of Study). | — |
Countries
India
Contacts
Public ContactDr Palaniyamma
The Himalaya Drug Company
Outcome results
None listed